Vor Bio Appoints Dr. Jeremy Sokolove As Chief Medical Officer To Advance Clinical Development In Autoimmune Diseases

Vor Bio, a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, has announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer. Dr. Sokolove brings over 20 years of clinical and translational experience in rheumatology and autoimmune disease research to the company’s leadership team, reinforcing Vor Bio’s commitment to advancing innovative therapies for patients with limited treatment options.

Dr. Sokolove has an extensive background in clinical medicine, research, and pharmaceutical development, combining his deep scientific expertise with hands-on patient care experience. Most recently, he served as Chief Medical Officer In-Residence at Roivant Sciences, where he was responsible for identifying and evaluating new therapeutic opportunities, providing clinical and translational leadership, and supporting development strategies across Roivant’s portfolio of biotech companies.

Before his tenure at Roivant, Dr. Sokolove was Chief Medical Officer at Odyssey Therapeutics, where he played a key role in transitioning the company into a clinical-stage biotechnology organization developing next-generation immunomodulators for autoimmune and inflammatory diseases. Earlier in his career, he held senior leadership positions at major global pharmaceutical companies, including serving as Senior Vice President and Head of Clinical Pharmacology and Experimental Medicine at GSK. In this role, he led early and translational development across the company’s specialty pharma portfolio. Prior to GSK, he worked at AbbVie as Head of Immunology Translational Science, where he oversaw early-stage clinical programs and designed strategies to connect preclinical science with clinical outcomes.

Dr. Sokolove began his career as a faculty member at Stanford University School of Medicine, where he practiced as a rheumatologist and served as a principal investigator. His academic research at Stanford focused on biomarker discovery and understanding the underlying mechanisms of immune-mediated diseases. Over the years, he has authored numerous publications in leading scientific journals, contributing significantly to advancements in immunology and rheumatology. He is board-certified in internal medicine and rheumatology and earned his medical degree from the Boston University School of Medicine.

Commenting on the appointment, Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board at Vor Bio, said, “We are thrilled to welcome Jeremy to Vor Bio. His expertise as a rheumatologist, combined with his proven leadership in clinical research and development, makes him an ideal fit to lead our clinical strategy. With his experience guiding programs in autoimmune and inflammatory diseases, we are confident that he will help us advance our dual BAFF/APRIL approach toward delivering meaningful benefits to patients.”

Expressing his enthusiasm about joining the company, Dr. Sokolove said, “I am joining Vor Bio because I see strong scientific and clinical potential in targeting the BAFF and APRIL pathways to precisely modulate the key mechanisms driving autoimmune diseases. Telitacicept, in particular, offers a differentiated opportunity to improve outcomes for patients who currently rely on broad immunosuppressive therapies. I look forward to collaborating with the Vor Bio team to execute a global clinical development program for Telitacicept and bring forward therapies that can truly make a difference in patients’ lives.”

Through this appointment, Vor Bio strengthens its clinical leadership and reaffirms its mission to develop targeted, science-driven therapies that address the root causes of autoimmune diseases and improve the quality of life for patients worldwide.